In 2019, Mesoblast Ltd (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategyhttp://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
In 2019, Mesoblast Ltd (MSB) plans to work diligently with the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
-0.015(0.92%) |
Mkt cap ! $2.063B | |||
| Open | High | Low | Value | Volume |
| $1.63 | $1.65 | $1.60 | $6.671M | 4.132M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 52401 | 4 |
View Market Depth
| Last trade - 16.10pm 07/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |